Research Article

Letrozole Potentiates Mitochondrial and Dendritic Spine Impairments Induced by β Amyloid

P. K.-Y. Chang, S. Boridy, R. A. McKinney, and D. Maysinger

Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, 3655 Promenade Sir William Osler, Montreal, QC, Canada H3G 1Y6

Correspondence should be addressed to R. A. McKinney; anne.mckinney@mcgill.ca and D. Maysinger; dusica.maysinger@mcgill.ca

Received 5 March 2013; Accepted 18 June 2013

Academic Editor: Holly M. Brown-Borg

Copyright © 2013 P. K.-Y. Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reduced estrogens, either through aging or postsurgery breast cancer treatment with the oral nonsteroidal aromatase inhibitor letrozole, are linked with declined cognitive abilities. However, a direct link between letrozole and neuronal deficits induced by pathogenic insults associated with aging such as beta amyloid ($\beta$Amyloid) has not been established. The objective of this study was to determine if letrozole aggravates synaptic deficits concurrent with $\beta$Amyloid insult. We examined the effects of letrozole and oligomeric $\beta$Amyloid treatment in dissociated and organotypic hippocampal slice cultures. Changes in glial cell morphology, neuronal mitochondria, and synaptic structures upon letrozole treatment were monitored by confocal microscopy, as they were shown to be affected by oligomeric $\beta$Amyloid. Oligomeric $\beta$Amyloid or letrozole alone caused decreases in mitochondrial volume, dendritic spine density, synaptophysin (synaptic marker), and the postsynaptic protein, synaptopodin. Here, we demonstrated that mitochondrial and synaptic structural deficits were exacerbated when letrozole therapy was combined with $\beta$Amyloid treatment. Our novel findings suggest that letrozole may increase neuronal susceptibility to pathological insults, such as oligomeric $\beta$Amyloid in Alzheimer’s disease (AD). These changes in dendritic spine number, synaptic protein expression, and mitochondrial morphology may, in part, explain the increased prevalence of cognitive decline associated with aromatase inhibitor use.

1. Introduction

Currently, aromatase inhibitors, leading to reduction of estradiol synthesis from testosterone, have been favoured in the treatment of breast cancer of postmenopausal women [1]. Letrozole is one such oral nonsteroidal aromatase inhibitor which prevents the aromatase from producing estrogens by competitive, reversible binding to the heme of its cytochrome P450 unit [2, 3]. Patients receiving letrozole have shown deficits in learning and memory [4]. However, it is still unclear if these functional impairments occur because of neurosteroid deficits and if they become exacerbated in the presence of an additional insult associated with aging, such as an excess of soluble, conformationally altered $\beta$Amyloid. Such forms of $\beta$Amyloid can interact with synapses and cause pronounced degenerative changes, an observation made in brain tissue from postmortem Alzheimer’s disease (AD) patients and animal models [5]. It has been well documented in AD that there are changes in neuronal and glial morphologies such as dendritic spine atrophy and increased glial growth [5, 6]. In contrast to these negative effects caused by $\beta$Amyloid, it is well established that the neurosteroid estradiol can increase the number of dendritic spines and proteins in humans, as well as promoting synaptogenesis and cellular models of learning such as long-term potentiation (LTP) in hippocampal cultures [7, 8]. Despite these well-established positive effects of neuroestrogens in the CNS, $\beta$estradiol hormone therapy in postmenopausal women did not exhibit clear cognitive benefits [9–13]. These clinical studies did not provide conclusive evidence whether exogenous estrogen exposure in early menopause affects AD or cognitive aging [14] and to what extent (if any) peripheral estrogen in blood could play a role in patients or animal models of AD [15–17].

To investigate whether aromatase suppression in the CNS affects synaptic responses to pathological insults, we used confocal microscopy to examine the effect of letrozole
and Aβ1–42 on two model systems, dissociated hippocampal neurons, and organotypic slice cultures. The slice cultures have a preserved neural circuitry, exhibit similar synaptic transmission as in vivo, and permit long-term studies allowing for the assessment of synapse morphology and function following pharmacological aromatase inhibition. The objective of the present study was to investigate the response of hippocampal neurons and glia to soluble Aβ1–42 species upon inhibition of CNS aromatase by letrozole. We have found significant decrease in neuronal mitochondrial volume, dendritic spine density, synapse number, and the synaptic protein, synaptophysin, in cultures that were either treated with letrozole or Aβ1–42 alone. With letrozole and Aβ1–42 co-treatment, the synaptic and mitochondrial deficits were further enhanced in the hippocampal neurons. These findings could explain why women on letrozole have a higher incidence of cognitive decline and may be more vulnerable to the detrimental effect of Aβ1–42.

2. Materials and Methods

2.1. Preparation of β-Amyloid (Aβ1–42). Aβ1–42 (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 5% NH4OH in Tris Buffered Saline and vortexed until fully dissolved (several minutes) at a concentration of 1 mM. Aliquots were stored at −80 °C. Upon reconstitution, aliquots are dissolved directly in media prior to treatment at a final concentration of 1 μM [18].

2.2. Preparation of Dissociated Neural Cell Cultures. All procedures for animal handling were carried out according to the guidelines of the Canadian Council on Animal Care (CCAC) and approved by the Animal Resource Committee of the School of Medicine, McGill University. Hippocampal tissues from mouse pups of 3–5 days old were dissected, trypsinized, dissociated, and incubated as described previously [19]. Briefly, hippocampi of P3–5 mice were isolated, mechanically and enzymatically (0.25% trypsin; Gibco, Life Technologies Inc, Burlington, ON, Canada), dissociated, and plated onto coated (poly-l-ornithine, 100 μg/mL (Sigma-Aldrich) and laminin, 0.587 μg/mL (Invitrogen, Life Technologies Inc, Burlington, ON, Canada)) glass coverslips and maintained at 37 °C and 5% CO2 in a 24-well plate (Corning; Lowell, MA, USA). Culture medium consisted of neurobasal A (Invitrogen) supplemented with 2% (v/v) B-27 supplement (Invitrogen), 1% (v/v) PSN (Invitrogen), and 1 mM L-glutamine (Sigma-Aldrich).

2.3. Pharmacological Treatments of Dissociated Neural Cell Cultures. Dissociated cells were treated on day in vitro (DIV) 8 with 1 μM letrozole (Novartis, Dorval, QC, Canada) and/or 1 μM Aβ1–42 (American Peptide Company, Sunnyvale, CA, USA) [20] according to the respective design outlined in the results section and corresponding figure legends.

2.4. Preparation of Slice Cultures. Hippocampal slices (400 μm) from P6–8 transgenic mice expressing membrane-targeted MARCKS-eGFP under the Thy-1 promoter in a subpopulation of CA1 cells [21] were prepared as previously described using the roller-tube method [22]. Slice cultures were maintained in the incubator with a roller-drum for three weeks before experimentation to allow for spine maturation [23].

2.5. Pharmacological Treatments of Slice Cultures. Slice cultures were maintained for at least 3 weeks in vitro to allow for maturation prior to treatment. In addition, all treatments were done on sister cultures (slice cultures that were prepared from the same mice litter and handled the same way at the same time). To prevent the effects of estradiol known to be present in serum, which is normally included in the culture media, we placed our preparations in serum free media prior to testing the effects of Aβ1–42 or letrozole [24]. Following preincubation, cultures were then treated with media containing either, vehicle, Aβ1–42 (1μM), letrozole (1μM), or Aβ1–42 + letrozole for 24 or 72 hours. No media change was performed during the time course.

2.6. Immunocytochemistry for Dissociated Cells. Following treatments, the hippocampal cells were fixed in 4% formaldehyde for 10 min at room temperature (RT), and routine immunocytochemical protocol was followed using mouse monoclonal anti-GFAP (1: 250; Molecular Probes, Life Technologies Inc, Burlington, ON, Canada), β-III tubulin (1: 100; Molecular Probes), and Alexa488-conjugated goat anti-mouse IgG (1:800; Invitrogen). The samples were counterstained with Hoechst 33258 (Molecular Probes), mounted onto glass slides (Vectashield H-1000, Vector, Burlingame, CA, USA), and sealed with clear nail polish.

2.7. Mitochondrial Labeling and Morphological Status. Morphological status of mitochondria was determined by labelling live cells (treated or untreated) with 500 nM Mitotracker Deep Red FM (Molecular Probes) for 3 minutes and imaged with a confocal microscope at 63x (Zeiss LSM510, Carl Zeiss MicroImaging GmbH, Jena, Germany); 633 nm HeNe laser at 20% max excitation intensity. Z-stacks (10 slices, 0.33 μm steps) were acquired of dendritic segments from 4–6 different neurons per coverslip, and 2-3 coverslips per condition were analyzed. 3D deconvolution of the raw stack was performed using Huygen’s Deconvolution Software (Scientific Volume Imaging, Hilversum, The Netherlands) with maximum likelihood extrapolation, and images were further analyzed for volumetric measurements using Imaris (Bitplane, Zurich, Switzerland).

2.8. Image Acquisition and Quantification of Dendritic Spines. Following treatments, slice cultures were transferred to a temperature-controlled chamber (30°C) mounted on an upright confocal microscope equipped with W Plan- APOCHROMAT 63x/1.0 objective (Zeiss LSM710, Carl Zeiss MicroImaging GmbH) and continuously perfused with Tyrode solution containing (in mM): NaCl, 137; KCl, 2.7; CaCl2, 2.5; MgCl2, 2; NaHCO3, 11.6; NaH2PO4, 0.4; and glucose, 5.6 (pH 7.4). Secondary and tertiary dendritic branches from either apical or basal dendrites of CA1 pyramidal neurons were imaged using 488 nm argon-ion laser line. Spine
3. Results

It has been previously shown that abnormalities in spine structure and composition are observed in response to aromatase inhibition; the present study considers the effects of soluble oligomeric $\text{A} \beta_{1-42}$ on characterized dendritic spine subtypes and mitochondrial structures in hippocampal neurons exposed to letrozole. Estrogens mediate neuroprotective effects in part through maintenance of mitochondrial structure and metabolic function [25, 26], and, thus far, letrozole’s effect on mitochondrial network plasticity has not been considered. Live dissociated mixed neural cultures treated for 24 hrs with 1 $\mu$M letrozole were labelled with the mitochondrial-specific probe, MitoTracker Deep Red FM (see methods and materials). Sectioning of isolated hippocampal dendrites followed by 3D reconstruction of the resultant image stacks using Imaris software allowed for mitochondrial volume measurement acquisition and thus a readout of mitochondrial integrity, following aromatase inhibition (Figure 1(a)). We found that letrozole treatment resulted in mitochondrial fragmentation, measured as a significant reduction in volume (Figure 1(b), control, 4.03 ± 0.56 $\mu$m$^3$; letrozole, 1.72 ± 0.49 $\mu$m$^3$; $P = 0.015$), implying mitochondrial dysfunction. Next, we thought to address the question of how does blockade of estrogen synthesis affect neuronal circuitry.

To this end, we examined the effects of estrogen synthesis inhibition on the morphological characteristics of neurons and glial cells using letrozole (Figure 2). Immunohistochemical analyses of colabelled neurons and glia from these mice using $\beta$-III tubulin as a neuronal marker and anti-glial fibrillary acidic protein (GFAP) as an astrocytic marker revealed profound changes in those cultures that
were treated with letrozole (1μM) for 72 hours: primary cultures that were treated with control media have extensive neuronal arbors and normal astrocytic morphology while striking changes were revealed in the letrozole-treated cultures where hippocampal neurons were sparse, with thin dendritic extensions, coupled with massive astrocytic hypertrophy (Figure 2(a)). When the letrozole treatments were repeated using organotypic hippocampal slice cultures, a culture system with more intact neuronal circuitry, we observed a significant loss of dendritic spines following 24 and 72 hours of letrozole treatment. These findings suggest that the aromatase-mediated blockade of estradiol synthesis with letrozole adversely affects neuronal circuitry in the hippocampus.
As the densities of dendritic spines are known to be modulated by estrogens [8], we investigated the effect of letrozole on spine density and shape (Figure 2(b) and Supplementary Table 1). See Supplementary material available online at http://dx.doi.org/10.1155/2013/538979. Treatments for 24 hours with letrozole led to a significant reduction in the number of CA1 dendritic spines compared to control slices (Figure 2(c) and Supplementary Table 1, stubby, $P = 2.1 \times 10^{-4}$; mushroom, $P = 1.0 \times 10^{-7}$; thin, $P = 2.1 \times 10^{-4}$; total, $P = 1.1 \times 10^{-5}$). Given the observed decrease in spine density, we subsequently investigated whether the significant decrease in spine density was subtype dependent (thick, stubby, and mushroom), which could serve as a correlate of the number of glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA)-type receptors and synapse strength [27]. All subtypes of the spines were affected with the different treatments after 24 hours. Next, we determined if the dendritic spine loss following the treatment is time dependent, and we examined spine densities after 72 hours of letrozole treatment (Figure 2(c) and Supplementary Table 1, stubby, $P = 7.6 \times 10^{-6}$; mushroom, $P = 3.3 \times 10^{-6}$; thin, $P = 1.8 \times 10^{-10}$; total, $P = 1.8 \times 10^{-10}$). We found, at 72 hours, a continued loss of dendritic spines compared to treatments after 24 hours. These findings show that reduction of estradiol concentrations due to the aromatase inhibition affects all spine subclasses with the most marked reduction in mushroom and thin spines.

Given that letrozole alone caused mitochondrial impairments and synaptic deficits, we next determined whether it could exacerbate changes in response to soluble oligomeric $\alpha\beta_{1-42}$, an established mediator of neuronal deficits associated with AD pathology. First, we examined the effect of oligomeric $\alpha\beta_{1-42}$ in conjunction with letrozole treatment on neuronal mitochondrial integrity (Figure 3). Mixed dissociated neural cultures were treated with $1 \mu M$ letrozole every 24 hours from DIV 6 to 8. On DIV 8, letrozole treatment was combined with oligomeric $\alpha\beta_{1-42}$ species ($1 \mu M$) for a subsequent 24 hours, following which mitochondria were labelled and imaged as described above. As shown in Figure 3(b), we observed a trend towards a decrease ($P = 0.26$) in mitochondrial volume when the neuronal cultures were treated with $\alpha\beta_{1-42}$ alone. We found a further reduction of mitochondrial volume when the cultures were pretreated with letrozole prior to oligomeric $\alpha\beta_{1-42}$ species exposure compared to either letrozole ($P = 0.17$) or $\alpha\beta_{1-42}$ alone ($P = 3.37 \times 10^{-4}$). Our data suggest that letrozole treatment sensitizes neuronal mitochondria to alterations induced by $\alpha\beta_{1-42}$ oligomers. Next, we examined whether these treatments can also lead to changes in synaptic structures.

Previously, it was shown that the addition of soluble oligomeric $\alpha\beta_{1-42}$ can cause a decrease in dendritic spine density [20]. Hence, we determined if the combined treatment with $\alpha\beta_{1-42}$ and letrozole exerts even greater impairments of mitochondrial integrity and synaptic structures. Treatments for 24 and 72 hours with either letrozole or $\alpha\beta_{1-42}$ alone lead to a significant reduction in the number of CA1 dendritic spines compared to control slices (Figure 4 and Supplementary Table 2, $P = 4.7 \times 10^{-5}$, $P = 1.1 \times 10^{-6}$, resp.). The decrease in spines can be attributed to a drop in mushroom and thin-type spines (Figure 4 and Supplementary
Figure 4: Letrozole and Aβ1–42 reduce the number of dendritic spines. (a) Representative 3D reconstructions of dendritic segments from sister cultures that were treated with either control, Aβ1–42 (1 μM), and letrozole (1 μM) or Aβ1–42 + letrozole (1 μM) for 24 or 72 hours. Scale bar, 2 μm. (b) Quantification of the spine subtype densities following treatments. There is a significant decrease in the total dendritic spine densities for Aβ1–42, letrozole, and Aβ1–42 + letrozole-treated cultures compared to control after 24 hours. When spine subtypes are examined, there are significant differences between control and treated cultures in mushroom and thin-type spines while spine density for stubby spines is only significantly different between letrozole and Aβ1–42 + letrozole compared to control and between Aβ1–42 and letrozole. Control, n = total dendritic segment lengths of 441 μm from 10 cells in 4 cultures; Aβ1–42, n = 428 μm of dendrite from 11 cells in 4 cultures; letrozole, n = 433 μm of dendrite from 9 cells in 4 cultures; Aβ1–42 + letrozole, n = 431 μm of dendrite from 10 cells in 4 cultures. There is a significant decrease in the total dendritic spine densities compared to control cultures after 72 hours as well. In total spine density, cultures treated with either letrozole or Aβ1–42 + letrozole had lower spine counts compared to cultures treated with Aβ1–42 alone. For mushroom and thin-type spines, cultures treated with both Aβ1–42 and letrozole had significantly lower spine densities compared to Aβ1–42 alone while stubby spine density was lower for letrozole-treated compared to Aβ1–42 alone. Control, n = 500 μm of dendrite from 12 cells in 4 cultures; Aβ1–42, n = 465 μm of dendrite from 10 cells in 4 cultures; letrozole, n = 489 μm of dendrite from 11 cells in 4 cultures; Aβ1–42 + letrozole, n = 441 μm of dendrite from 9 cells in 4 cultures. Only cultures treated with Aβ1–42 + letrozole had significant decrease in total spine densities between 24 and 72 hours of treatment. This difference is contributed by significant decrease in spine density in both mushroom and thin type spines.
Table 2, mushroom: $A_{1-42}$, $P = 1.7 \times 10^{-8}$; letrozole, $P = 1.0 \times 10^{-7}$; thin: $A_{1-42}$, $P = 2.1 \times 10^{-3}$; letrozole, $P = 2.1 \times 10^{-4}$; while spine density for stubby spines is only significantly different between letrozole and $A_{1-42} +$ letrozole compared to control (letrozole, $P = 2.1 \times 10^{-4}$; $A_{1-42} +$ letrozole, $P = 2.1 \times 10^{-7}$) and between $A_{1-42}$ and letrozole ($P = 0.014$). In addition, treatments at 72 hours revealed a further reduction in dendritic spine densities in the slice cultures that were treated with both $A_{1-42}$ and letrozole compared to $A_{1-42}$ alone (Figure 4 and Supplementary Table 2, $P = 1.9 \times 10^{-11}$). In total spine density, cultures treated with either letrozole or $A_{1-42} +$ letrozole had lower spine count compared to cultures treated with $A_{1-42}$ alone ($P = 0.036$ and $3.3 \times 10^{-4}$ resp.). For mushroom and thin-type spines, cultures treated with both $A_{1-42}$ and letrozole had significantly lower spine densities compared to $A_{1-42}$ alone (mushroom, $P = 0.024$; thin, $P = 0.013$) while stubby spine density was lower for letrozole-treated cultures compared to $A_{1-42}$ alone ($P = 7.0 \times 10^{-3}$). Furthermore, to examine whether the observed dendritic spine loss was indeed caused by estradiol depletion using letrozole, we treated the slice cultures with letrozole, $A_{1-42}$, and letrozole + $A_{1-42}$ in the presence of estradiol (Supplementary Figure 1, Supplementary Tables 1 and 4, estradiol). We have found that cotreatment with estradiol successfully prevented the decrease in dendritic spine density caused by letrozole and/or $A_{1-42}$, as no change in spine densities was observed compared to control at 24 or 72 hours (24 hours: estradiol, $P = 0.13$; estradiol + letrozole, $P = 0.38$; estradiol + $A_{1-42}$, $P = 0.22$; estradiol + letrozole + $A_{1-42}$, $P = 0.37$; 72 hours, estradiol, $P = 0.57$; estradiol + letrozole, $P = 0.18$; estradiol + $A_{1-42}$, $P = 0.69$; estradiol + letrozole + $A_{1-42}$, $P = 0.61$). These data provide substantial evidence that letrozole can worsen neuronal deficits caused by oligomeric $A_{1-42}$.

Although dendritic spines density was decreased after letrozole and $A_{1-42}$ treatment, it has been shown that the loss of spine does not necessary mean the loss of synapses [28]. In some instances, presynaptic terminals may be pulled back onto the dendrite to form asymmetric shaft synapses [28]. To answer the question if the observed loss of postsynaptic dendritic spines is accompanied by a loss of presynaptic terminals, we performed immunohistochemistry labelling of synaptophysin (presynaptic terminal marker). This presynaptic marker allows the determination of a loss or gain of presynaptic terminals when there is a loss (or gain) of dendritic spines induced by therapeutic treatments or insults to the CNS (Figure 5 and Supplementary Table 3). There was a significant decrease in synaptopodin puncta after 24 hours which became more pronounced at 72 hours of letrozole or $A_{1-42} +$ letrozole treatments compared to control conditions (24 hours: $A_{1-42}$, $P = 6.1 \times 10^{-2}$; letrozole, $P = 7.3 \times 10^{-6}$; $A_{1-42} +$ letrozole, $P = 1.2 \times 10^{-7}$); 72 hour, $A_{1-42}$, $P = 4.0 \times 10^{-6}$; letrozole, $P = 4.0 \times 10^{-6}$; $A_{1-42} +$ letrozole, $P = 4.0 \times 10^{-6}$). After 72 hours, the number of synaptopodin puncta was significantly lower in letrozole and $A_{1-42} +$ letrozole-treated cultures compared to $A_{1-42}$ alone (letrozole, $P = 0.043$; $A_{1-42} +$ letrozole, $P = 2.0 \times 10^{-3}$). When synaptopodin puncta densities were compared between 24- and 72-hour treated cultures there was a significant decrease in $A_{1-42}$, letrozole, and $A_{1-42} +$ letrozole-treated cultures after 72 hours ($A_{1-42}$, $P = 1.1 \times 10^{-4}$; letrozole, $P = 1.0 \times 10^{-7}$; and $A_{1-42} +$ letrozole, $P = 1.4 \times 10^{-8}$).

We next investigated if there was also a loss of synaptopodin, an actin-binding protein mainly found in a subgroup of mature spines. Synaptopodin is known to be downregulated upon exposure to estradiol [29]. It also plays a role in learning and memory; synaptopodin knockout animals have reduced LTP and have deficits in spatial learning [30]. We found that there is a change in synaptopodin staining after treatment with $A_{1-42}$, letrozole, and $A_{1-42} +$ letrozole (Figure 5 and Supplementary Table 3). There was a significant decrease in synaptopodin puncta after 24 and 72 hours of treatments compared to control (Figure 5 and Supplementary Table 3; 24 hours, $A_{1-42}$, $P = 4.1 \times 10^{-6}$; letrozole, $P = 4.0 \times 10^{-6}$; $A_{1-42} +$ letrozole, $P = 4.0 \times 10^{-6}$; 72 hours, $A_{1-42}$, $P = 2.2 \times 10^{-6}$; letrozole, $P = 3.9 \times 10^{-6}$; $A_{1-42} +$ letrozole, $P = 3.9 \times 10^{-6}$). After 72 hours, the number of synaptopodin puncta was significantly lower in letrozole and $A_{1-42} +$ letrozole-treated cultures compared to $A_{1-42}$ alone (letrozole, $P = 1.2 \times 10^{-7}$; $A_{1-42}$, $P = 3.9 \times 10^{-6}$). When synaptopodin puncta densities were compared between 24- and 72-hour treated cultures, there was a significant decrease in $A_{1-42}$ ($P = 4.1 \times 10^{-6}$), letrozole ($P = 4.0 \times 10^{-6}$), and $A_{1-42} +$ letrozole ($P = 4.0 \times 10^{-6}$)-treated cultures after 72 hours. Difference between controls was not significant ($P = 0.09$). Decreases in estrogen levels reduced the number of synaptic connections, and this was more pronounced in the presence of $A_{1-42}$.

4. Discussion

Chronic estrogen deficit, similar to that experienced by menopausal women, is a recognized risk factor for AD [31]. The neurological deficits known to result from estrogen deficiency are accompanied by morphological deterioration of postsynaptic spines and functional impairments of mitochondria. We have now shown similar pathological features in an animal model with estrogen deficiency [32] and in neural cells of normal animals with estrogen deficiency induced by letrozole, a therapeutic agent for breast cancer. However, in both instances, the more marked dendritic spine degeneration was produced only when letrozole treatment was together with oligomeric $A_{1-42}$.

Dendritic atrophy and astrocytic hypertrophy are common observations in many neurological disorders [6], including AD [33]. Although it was very clear that both circulating and brain estrogens were reduced in animal models and can lead to learning deficits, the contribution of neuroestrogens versus circulating estradiol could not be determined [15, 34]. To circumvent this, we used hippocampal organotypic cultures treated with the aromatase inhibitor, letrozole. This experimental paradigm allowed us to control the concentration and duration of aromatase inhibition and estrogen deficit. Moreover, this model is optimal for studying neuronal connections and glial input in a spatiotemporal (longitudinal)
Figure 5: Letrozole and Aβ1-42 reduce synaptic proteins. (a) Representative 3D reconstructions of dendritic segments from sister cultures that were treated with either control, Aβ1-42 (1 μM), and letrozole (1 μM) or Aβ1-42 + letrozole (1 μM) for 24 or 72 hours and immunostained for synaptophysin (white) and synaptopodin (red). Scale bar, 2 μm. (b) Quantification of the densities of synaptopodin-positive puncta following treatments. There is a significant decrease in synaptopodin puncta after 24 and 72 hours of Aβ1-42, letrozole or Aβ1-42 + letrozole treatments compared to control conditions. After 72 hours, the number of synaptopodin puncta was significantly lower in letrozole and Aβ1-42 + letrozole-treated cultures compared to Aβ1-42 alone. When synaptopodin puncta densities were compared between 24- and 72-hour treated cultures there was a significant decrease only in letrozole and Aβ1-42 + letrozole-treated cultures after 72 hours. 24 hours: control, n = total dendritic segment lengths of 1041 μm from 12 cells in 4 cultures; Aβ1-42, n = 633 μm of dendrite from 8 cells in 4 cultures; letrozole, n = 952 μm of dendrite from 10 cells in 4 cultures; Aβ1-42 + letrozole, n = 1007 μm of dendrite from 10 cells in 4 cultures. 72 hours: control, n = total dendritic segment lengths of 559 μm from 10 cells in 3 cultures; Aβ1-42, n = 472 μm of dendrite from 9 cells in 4 cultures; letrozole, n = 838 μm of dendrite from 9 cells in 4 cultures; Aβ1-42 + letrozole, n = 750 μm of dendrite from 8 cells in 4 cultures. There is a significant decrease in synaptophysin puncta after 24 and 72 hours of Aβ1-42, letrozole, or Aβ1-42 + letrozole treatments compared to control conditions. After 72 hours, the number of synaptophysin puncta was significantly lower in letrozole and Aβ1-42 + letrozole-treated cultures compared to Aβ1-42 alone. When synaptophysin puncta densities were compared between 24- and 72-hour treated cultures there was a significant decrease in Aβ1-42, letrozole, and Aβ1-42 + letrozole-treated cultures after 72 hours. 24 hours: control, n = total dendritic segment lengths of 1041 μm from 12 cells in 4 cultures; Aβ1-42, n = 633 μm of dendrite from 8 cells in 4 cultures; letrozole, n = 952 μm of dendrite from 10 cells in 4 cultures; Aβ1-42 + letrozole, n = 1007 μm of dendrite from 10 cells in 4 cultures. 72 hours: control, n = total dendritic segment lengths of 559 μm from 10 cells in 3 cultures; Aβ1-42, n = 472 μm of dendrite from 9 cells in 4 cultures; letrozole, n = 838 μm of dendrite from 9 cells in 4 cultures; Aβ1-42 + letrozole, n = 750 μm of dendrite from 8 cells in 4 cultures.
Typical astrocyte morphology

Typical dendritic spine density

Normal mitochondrial homeostasis (fission and fusion)

Normal synaptophysin expression (presynaptic)

Normal synaptopodin expression (postsynaptic)

No aromatase inhibition

Aromatase inhibition with letrozole

Astrocyte hypertrophy

Dendritic spine loss

Decreased synaptophysin expression (presynaptic)

Decreased synaptopodin expression (postsynaptic)

Impaired mitochondrial homeostasis (fission)

Figure 6: Summarising schematic: aromatase inhibition leads to synaptic and mitochondrial deficits. (a) Aromatase-mediated conversion of testosterone to estrogen in astrocytes serves as a local reservoir of neuroestrogens to promote maintenance of dendritic spines and synaptic mitochondrial integrity. (b) Aromatase inhibition by letrozole leads to spine loss, pre- and postsynaptic protein deficits, and compromised mitochondrial integrity.

manner, in parallel with studies of mitochondrial responses to local estrogen deficits.

Functional and morphological impairment of synaptic mitochondria was associated with accumulation of \( A\beta_{1-42} \) in AD animal models [35, 36]. How does this relate to synaptic functions? Neuronal activity was shown to increase mitochondrial fission and entry of mitochondria into dendritic spines [37]; however fission is also initiated to sequester dysfunctional mitochondrial components and to facilitate apoptosis associated with neurodegenerative changes [38]. Recently, it has been suggested that mitochondria associated with dendritic spines may play an important role in regulating AMPA receptor trafficking, which is altered in the presence of \( A\beta_{1-42} \) oligomers [5, 39]. We were interested in whether changes in mitochondrial morphology under conditions of reduced estrogen synthesis in the presence of \( A\beta_{1-42} \) oligomers, were associated with synaptic deficits. We noted a significant decrease in mitochondrial volume, suggesting fission after \( A\beta_{1-42} \), letrozole, or combined treatments with both. These observations are therefore in line with our present understanding of how synaptic degeneration relates to mitochondrial impairment.

Our results also suggest that estradiol may play a role in regulating the balance between the two opposing processes of mitochondrial fission and fusion. Dynamics between these two processes maintains mitochondrial homeostasis in healthy cells but is disrupted in AD [40, 41]. Findings reported in this study are in accordance with recent findings indicating a role for \( A\beta_{1-42} \) in the regulation of mitochondrial fission in AD [40, 42]. Further emphasizing the importance
of mitochondria in spine maintenance, impairment of mitochondrial transport to synapses by $Aβ_{1-42}$ has been reported to contribute to AMPAR removal and trafficking defects leading to synaptic inhibition [39].

In order to further understand how these disturbances in mitochondrial dynamics affect neuronal plasticity and function, we next investigated dendritic spine morphology, density, and synaptic proteins, following similar treatments. We examined changes in synaptophysin, a presynaptic marker, and synaptopodin, an actin binding protein, mainly found in a subgroup of mature spines and is regulated by estradiol [29]. The precise role of synaptopodin in hippocampal neurons is still unclear but has been shown to be important in learning and memory and in glutamate functions [30]. Our data show a significant reduction of pre- and postsynaptic components and synaptopodin with $Aβ_{1-42}$ and letrozole treatment.

Taken together, present results suggest that the neurological deficits seen in women on letrozole therapy for breast cancer could result, at least in part, from the therapy-induced hippocampal estrogen deficiency (Figure 6). Herein, we demonstrate that dendritic spine and mitochondrial deteriorations are particularly prominent in states of central hypoestrogenicity (Figure 6, lower half) and can further increase hippocampal susceptibility to spine/synaptic loss or mitochondrial functional impairment induced by a pathological insult. An important outcome of the current studies is the recognition that caution must be exercised in the use of letrozole as a therapy for breast cancer, and that account must be taken especially of the age of the female patient and/or presence of other recognised risk factors for AD. Given that letrozole is highly lipophilic and can cross the blood brain barrier, its incorporation into a nanodelivery system to prevent its access to the brain and at the same time enhance accumulation in the tumor warrants consideration.

**Conflict of Interests**

The authors declare they have no competing financial interests.

**Author’s Contribution**

D. Maysinger and R. A. McKinney designed the experiments and consulted the students. P. K.-Y. Chang, S. Boridy, D. Maysinger, and R. A. McKinney wrote the draft and edited the final version of the paper. P. K.-Y. Chang performed all the experiments with hippocampal organotypic cultures, analyzed the data, and prepared Figures 2, 4, and 5. S. Boridy performed experiments with primary cultures and data analyses and prepared Figures 1 and 3. P. K.-Y. Chang and S. Boridy contributed equally to this paper.

**Acknowledgments**

The authors would like to thank François Charron for all his technical expertise in preparing the organotypic slice cultures. The work was supported by Grants from the Canadian Institute of Health Research and the Alzheimer’s Society of Canada.

**References**

[1] V. F. Semiglazov, V. V. Semiglazov, G. A. Dashyan et al., “Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer,” Cancer, vol. 110, no. 2, pp. 244–254, 2007.

[2] J. V. A. Choate and J. A. Resko, “Paradoxical effect of an aromatase inhibitor, CGS 20267, on aromatase activity in guinea pig brain,” Journal of Steroid Biochemistry and Molecular Biology, vol. 58, no. 4, pp. 411–415, 1996.

[3] B. P. Haynes, M. Dowsett, W. R. Miller, J. M. Dixon, and A. S. Bhatnagar, “The pharmacology of letrozole,” Journal of Steroid Biochemistry and Molecular Biology, vol. 87, no. 1, pp. 35–45, 2003.

[4] V. Shilling, V. Jenkins, L. Fallowfield, and T. Howell, “The effects of hormone therapy on cognition in breast cancer,” Journal of Steroid Biochemistry and Molecular Biology, vol. 86, no. 3-5, pp. 405–412, 2003.

[5] P. Penzes, M. E. Cahill, K. A. Jones, J.-E. Vanleeuwen, and K. M. Woolfrey, “Dendritic spine pathology in neuropsychiatric disorders,” Nature Neuroscience, vol. 14, no. 3, pp. 285–293, 2011.

[6] M. V. Sofroniew and H. V. Vinters, “Astrocytes: biology and pathology,” Acta Neuropathologica, vol. 119, no. 1, pp. 7–35, 2010.

[7] J. Prange-Kiel, L. Fester, L. Zhou, H. Jarry, and G. M. Rune, “Estrus cyclicity of spinogenesis: underlying mechanisms,” Journal of Neurotransmission, vol. 116, no. 11, pp. 1417–1425, 2009.

[8] R. Vierk, G. Glassmeier, L. Zhou et al., “Aromatase inhibition abolishes LTP generation in female but not in male mice,” The Journal of Neuroscience, vol. 32, no. 24, pp. 8116–8126, 2012.

[9] P. Polo-Kantola, R. Portin, O. Polo, H. Helenius, K. Irjala, and R. Erkkola, “The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women,” Obstetrics and Gynecology, vol. 91, no. 3, pp. 459–466, 1998.

[10] E. Hogervorst, J. Williams, M. Budge, W. Riedel, and J. Jolles, “The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis,” Neuroscience, vol. 101, no. 3, pp. 485–512, 2000.

[11] O. T. Wolf, B. M. Kudielka, D. H. Hellhammer, S. Törber, B. S. McEwen, and C. Kirschbaum, “Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: verbal memory changes are associated with the treatment induced estradiol levels,” Psychoneuroendocrinology, vol. 24, no. 7, pp. 727–741, 1999.

[12] T. Duka, R. Tasker, and J. F. McGowan, “The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females,” Psychopharmacology, vol. 149, no. 2, pp. 129–139, 2000.

[13] A. Kugaya, C. N. Epperson, S. Zoghibi et al., “Increase in prefrontal cortex serotonin2A receptors following estrogen treatment in postmenopausal women,” American Journal of Psychiatry, vol. 160, no. 8, pp. 1522–1524, 2003.

[14] V. W. Henderson, “Action of estrogens in the aging brain: dementia and cognitive aging,” Biochimica et Biophysica Acta, vol. 1800, no. 10, pp. 1077–1083, 2010.

[15] D. Caruso, A. M. Barron, M. A. Brown et al., “Age-related changes in neuroactive steroid levels in 3xTg-AD mice,” Neurobiol Aging, vol. 34, pp. 1080–1089, 2013.
[16] C. R. Overk, P.-Y. Lu, Y.-T. Wang et al., “Effects of aromatase inhibition versus gonadectomy on hippocampal complex amyloid pathology in triple transgenic mice,” *Neurobiology of Disease*, vol. 45, no. 1, pp. 479–487, 2012.

[17] J. C. Carroll, E. R. Rosario, L. Chang et al., “Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice,” *Journal of Neuroscience*, vol. 27, no. 48, pp. 13357–13365, 2007.

[18] W. Wei, L. N. Nguyen, H. W. Kessels, H. Hagiwara, S. Sisodia, and R. Malinow, “Amyloid beta from axons and dendrites reduces local spine number and plasticity,” *Nature Neuroscience*, vol. 13, no. 2, pp. 190–196, 2010.

[19] S. Boridy, H. Takahashi, K. Akiyoshi, and D. Mayssinger, “The binding of pullulan modified cholesteryl nanogels to Aβ oligomers and their suppression of cytotoxicity,” *Biomaterials*, vol. 30, no. 29, pp. 5583–5591, 2009.

[20] H. Hsieh, J. Boehm, C. Sato et al., “AMPA removal underlies Aβ-induced synaptic depression and dendritic spine loss,” *Neuron*, vol. 52, no. 5, pp. 831–843, 2006.

[21] V. De Paola, S. Arber, and P. Caroni, “AMPA receptors regulate dynamic equilibrium of presynaptic terminals in mature hippocampal networks,” *Nature Neuroscience*, vol. 6, no. 5, pp. 491–500, 2003.

[22] B. H. Gähwiler, M. Capogna, D. Debanne, R. A. McKinney, and S. M. Thompson, “Organotypic slice cultures: a technique that has come of age,” *Trends in Neurosciences*, vol. 20, no. 10, pp. 471–477, 1997.

[23] R. A. McKinney, M. Capogna, R. Dürr, B. H. Gähwiler, and S. M. Thompson, “Miniature synaptic events maintain dendritic spines via AMPA receptor activation,” *Nature Neuroscience*, vol. 2, no. 1, pp. 44–49, 1999.

[24] P. Mendez, L. M. Garcia-Segura, and D. Muller, “ Estradiol promotes spine growth and synapse formation without affecting pre-established networks,” *Hippocampus*, vol. 21, no. 12, pp. 1263–1267, 2011.

[25] A. Grimm, Y. A. Lim, A. G. Mensah-Nyagan, J. Gotz, and A. Eckert, “Alzheimer's disease, oestrogen and mitochondria: an ambiguous relationship,” *Molecular Neurobiology*, vol. 46, pp. 151–160, 2012.

[26] J. W. Simpkins, K. D. Yi, S.-H. Yang, and J. A. Dykens, “Mitochondrial mechanisms of estrogen neuroprotection,” *Biochimica et Biophysica Acta*, vol. 1800, no. 10, pp. 1113–1120, 2010.

[27] M. Matsuzaki, G. C. R. Ellis-Davies, T. Nemoto, Y. Miyashita, M. Iino, and H. Kasai, “Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons,” *Nature Neuroscience*, vol. 4, no. 11, pp. 1086–1092, 2001.

[28] J. M. Mateos, A. Lüthi, N. Savic et al., “Synaptic modifications at the CA3-CA1 synapse after chronic AMPA receptor blockade in rat hippocampal slices,” *Journal of Physiology*, vol. 581, no. 1, pp. 129–138, 2007.

[29] L. Fester, L. Zhou, C. Voets et al., “The opposing roles of estradiol on synaptic protein expression in hippocampal cultures,” *Psychoneuroendocrinology*, vol. 34, supplement 1, pp. S123–S129, 2009.

[30] A. Vlachos, E. Korkotian, E. Schonfeld, E. Copanaki, T. Deller, and M. Segal, “Synaptophysin regulates plasticity of dendritic spines in hippocampal neurons,” *Journal of Neuroscience*, vol. 29, no. 4, pp. 1017–1033, 2009.

[31] S. C. Janicki and N. Schupf, “Hormonal influences on cognition and risk for Alzheimer's disease,” *Current Neurology and Neuroscience Reports*, vol. 10, no. 5, pp. 359–366, 2010.

[32] A. Prat, M. Behrendt, E. Marcinkiewicz et al., “A novel mouse model of Alzheimer's disease with chronic estrogen deficiency leads to glial cell activation and hypertrophy,” *Journal of Aging Research*, vol. 2011, Article ID 251517, 12 pages, 2011.

[33] J. L. Furman, D. M. Sama, J. C. Gant et al., “Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease,” *The Journal of Neuroscience*, vol. 32, pp. 16129–16140, 2012.

[34] F. Liu, M. Day, L. C. Muñiz et al., “Activation of estrogen receptor-β regulates hippocampal synaptic plasticity and improves memory,” *Nature Neuroscience*, vol. 11, no. 3, pp. 334–343, 2008.

[35] H. Du, L. Guo, S. Yan, A. A. Sosunov, G. M. McKhann, and S. S. Yan, “Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 43, pp. 18670–18675, 2010.

[36] S. J. Baloyannis, “Mitochondria are related to synaptic pathology in Alzheimer's disease,” *International Journal of Alzheimer's Disease*, Article ID 305395, 2011.

[37] J. Y. Sung, O. Engmann, M. A. Teylan, A. C. Nairn, P. Greengard, and Y. Kim, “WAVE1 controls neuronal activity-induced mitochondrial distribution in dendritic spines,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 8, pp. 3112–3116, 2008.

[38] R. J. Youle and A. M. van der Bliek, “Mitochondrial fission, fusion, and stress,” *Science*, vol. 337, pp. 1062–1065, 2012.

[39] Y. Rui, J. Gu, K. Yu, H. C. Hartzell, and J. Q. Zheng, “Inhibition of AMPA receptor trafficking at hippocampal synapses by amyloid oligomers: the mitochondrial contribution,” *Molecular Brain*, vol. 5, no. 1, article 10, 2010.

[40] X. Zhu, G. Perry, M. A. Smith, and X. Wang, “Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease,” *Journal of Alzheimer's Disease*, vol. 33, pp. S253–S262, 2013.

[41] E. Trushina, E. Nemutlu, S. Zhang et al., “Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial alzheimer's disease,” *PLoS ONE*, vol. 7, no. 2, Article ID e32737, 2012.

[42] B. Westermann, “Nitric oxide links mitochondrial fission to Alzheimer's disease,” *Science Signaling*, vol. 2, no. 69, p. pe29, 2009.